Drug Profile
PBF 2828
Alternative Names: PBF-1509; PBF-2828Latest Information Update: 14 May 2019
Price :
$50
*
At a glance
- Originator Palobiofarma
- Class Antineoplastics
- Mechanism of Action 5-nucleotidase inhibitors; CD39 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 May 2019 Discontinued for Cancer in Spain (Palobiofarma pipeline, May 2019)
- 20 Oct 2017 Early research in Cancer in Spain (unspecified route) before October 2017 (Palobiofarma pipeline, October 2017)